A Randomized, Double-Blind, Placebo-Controlled, Pilot Trial Of Individualized Homeopathic Medicines For Cutaneous Warts

Background Though frequently used in practice, research studies have shown inconclusive benefits of homeopathy in the treatment of warts. We aimed to assess the feasibility of a future definitive trial, with preliminary assessment of differences between effects of individualized homeopathic (IH) medicines and placebos in treatment of cutaneous warts.Methods A double-blind, randomized, placebo-controlled trial ( n =60) was conducted at the dermatology outpatient department of D.N. De Homoeopathic Medical College and Hospital, West Bengal. Patients were randomized to receive either IH ( n =30) or identical-looking placebo ( n =30). Primary outcome measures were numbers and sizes of the warts; secondary outcome was the Dermatology Life Quality Index (DLQI) questionnaire measured at baseline, and every month up to 3 months. Group differences and effect sizes were calculated on the intention-to-treat sample.Results Attrition rate was 11.6% (IH, 3; placebo, 4). Intra-group changes were significantly greater (all p <0.05, Friedman tests) in IH than placebo. Inter-group differences were statistically non-significant (all p >0.05, Mann-Whitney U tests) with small effect sizes-both in the primary outcomes (number of warts after 3 months: IH median [inter-quartile range; IQR] 1 [1, 3] vs. placebo 1 [1, 2]; p =0.741; size of warts after 3 months: IH 5.6mm [2.6, 40.2] vs. placebo 6.3 [0.8, 16.7]; p =0.515) and in the secondary outcomes (DLQI total after 3 months: IH 4.5 [2, 6.2] vs. placebo 4.5 [2.5, 8]; p =0.935). Thuja occidentalis (28.3%), Natrum muriaticum (10%) and Sulphur (8.3%) were the most frequently prescribed medicines. No harms, homeopathic aggravations, or serious adverse events were reported.Conclusion As regards efficacy, the preliminary study was inconclusive, with a statistically non-significant direction of effect favoring homeopathy. The trial succeeded in showing that an adequately powered definitive trial is both feasible and warranted.Trial Registration CTRI/2019/10/021659; UTN: U1111-1241-7340